Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
36 Results for "
LTB4 receptor
" in MedChemExpress (MCE) Product Catalog:
Products (36)
36 Results for "LTB4 receptor" in MCE Product Catalog:
4
4 Cited Publications
Target:
Research Areas:
J-113863 is a potent and selective CCR1 antagonist with IC50 values of 0.9 nM and 5.8 nM for human and mouse CCR1 receptors, respectively. J-113863 is also a potent antagonist of the human CCR3 (IC50 of 0.58 nM) , but a weak antagonist of the mouse CCR3 (IC50 of 460 nM). J-113863 is inactive against CCR2, CCR4 and CCR5, as well as the LTB4 or TNF-α receptors. Anti-inflammatory effect .
3
3 Cited Publications
Target:
Research Areas:
LY255283 is a LTB4 receptor (BLT2) antagonist, with an IC50 of ~100 nM for [ 3H]LTB4 binding to guinea pig lung membranes .
2
2 Cited Publications
Synonyms: LY293111; VML 295
Target:
Research Areas:
Etalocib (LY293111), an orally active leukotriene B4 receptor antagonist, inhibits the binding of [ 3H]LTB4, with a Ki of 25 nM. Etalocib (LY293111) prevents LTB4-induced calcium mobilization with an lC50 of 20 nM. Etalocib (LY293111) induces apoptosis .
1
1 Cited Publications
Target:
Research Areas:
BIIL-260 hydrochloride is a potent and long-acting orally active leukotriene B(4) receptor LTB4 antagonist, with anti-inflammatory activity. BIIL-260 hydrochloride interacts with the LTB4 receptor in a saturable, reversible, and competitive manner, has high affinity to the LTB4 receptor on isolated human neutrophil cell membranes with Ki values of 1.7 nM .
1
1 Cited Publications
Target:
Research Areas:
SB-209247 is a selective, high affinity and orally active leukotriene B4 (LTB4) receptor antagonist with a Ki of 0.78 nM. SB-209247 blocks LTB4-induced Ca 2+ mobilization with an IC50 of 6.6 nM. SB-209247 shows a potent anti-inflammatory activity .
1
1 Cited Publications
Synonyms: CGS 25019C free base
Target:
Research Areas:
Moxilubant (CGS 25019C free base) is an orally active BLT1 antagonist. Moxilubant inhibits LTB4 signaling with a potency of 2-4 nM. Moxilubant blocks LTB4-induced neutrophil functions. Moxilubant inhibits ear edema and neutrophil infiltration in mice. Moxilubant can be used in research related to chronic obstructive pulmonary disease .
Synonyms: CGS23131; SKF107324
Target:
Research Areas:
LY223982 is a potent and specific inhibitor of leukotriene B4 receptor, with an IC50 of 13.2 nM against [ 3H]LTB4 binding to LTB4 receptor.
Cat. No.: HY-19304
CAS No.: 346735-24-8
Synonyms: BIIL 284
Target:
Research Areas:
Amelubant (BIIL 284) is a potent, oral and long acting LTB4 receptor antagonist, negligibly binds to LTB4 receptor, with Kis of 221 nM and 230 nM in vital cells and membranes. Amelubant (BIIL 284) is a proagent of active metabolites BIIL 260 and BIIL 315. Anti-inflammatory activity .
Synonyms: Ethyl γ-linolenate
Target:
Research Areas:
γ-Linolenic acid ethyl ester (Ethyl γ-linolenate) is a leukotriene B4 receptor 4 (LTB4) antagonist .
Synonyms: 20-COOH LTB4
Target:
Research Areas:
20-Carboxy-Leukotriene B4 (20-COOH LTB4) is a metabolite of Leukotriene B4 (LTB4; HY-107608). 20-Carboxy-Leukotriene B4 binds to the BLT1 receptor with high affinity. 20-Carboxy-Leukotriene B4 inhibits LTB4-mediated neutrophil responses (migration, degranulation, leukotriene biosynthesis) .
Cat. No.: HY-112742
CAS No.: 204981-48-6
Target:
Research Areas:
CP-195543 is a potent, selective and orally active leukotriene B4 (LTB4) receptor antagonist with IC50s of 6.8, 37.0 nM for human neutrophils and murine spleen membranes, respectively. CP-195543 blocks CD11b up-regulation. CP-195543 inhibits LTB4-mediated neutrophil infiltration .
Cat. No.: HY-N4267
CAS No.: 13060-14-5
Cat. No.: HY-112740
CAS No.: 153633-01-3
Target:
Research Areas:
SC-53228 is an orally active human leukotriene B4 receptor (LTB4 receptor) antagonist. SC-53228 exerts its anti-inflammatory effect by specifically blocking the LTB4 receptor and inhibiting neutrophil infiltration. SC-53228 has demonstrated significant efficacy and good safety in various inflammatory models. SC-53228 can be used for a variety of inflammatory diseases, such as psoriasis and ulcerative colitis .
Cat. No.: HY-100173
CAS No.: 491577-61-8
Target:
Research Areas:
DW-1350 is a LTB4 receptor antagonist.
Research Areas:
Ricinelaidic acid, a 12-hydroxy fatty acid，is a leukotriene B4 (LTB4) receptor antagonist with the Ki of 2 μM in porcine neutrophil membranes. Ricinelaidic acid inhibits chemotaxis and calcium flux induced by LTB4 in isolated human neutrophils (IC50=10 and 7 μM, respectively). Ricinelaidic acid inhibits bronchoconstriction induced by LTB4 in rats .
Cat. No.: HY-115390
CAS No.: 114616-11-4
Target:
Research Areas:
14,15-Dehydro Leukotriene B4 (Compound 4) is a LTB4 receptor antagonist. 14,15-Dehydro Leukotriene B4 also has a higher binding affinity for BLT1 with a Ki value of 27 nM and BLT2 with a Ki value of 473 nM. 14,15-Dehydro Leukotriene B4 inhibits LTB4-induced release of lysozymes from rat polymorphonuclear leukoctyes with an IC50 value of 1 µM .
Cat. No.: HY-149083
CAS No.: 2929239-85-8
Target:
Research Areas:
LTB4 antagonist 2, a carboxamide-acid compound, is an antagonist of leukotriene B4 (LTB4) with potentially anti-inflammatory activity. LTB4 antagonist 2 shows good affinity for the LTB4 receptor with IC50 of 439 nM .
Cat. No.: HY-141635
CAS No.: 61012-46-2
Target:
Research Areas:
cis-11,14-Eicosadienoic acid methyl ester is a more lipid soluble form of the ω-6 C20-2 fatty acid 11(Z),14(Z)-eicosadienoic acid, a naturally occurring PUFA. 11(Z),14(Z)-Eicosadienoic acid competitively inhibits inosine 5’-monophosphate dehydrogenase (Ki=3.1 μM) and inhibits the binding of LTB4 to its receptor on neutrophils (Ki=3.0 μM). Also, serum levels of eicosadienoic acids negatively correlate with degree of sleep disturbance.3 Eicosadienoic acids are converted by desaturases, in vivo, to eicosatrienoic acids, which are potent vasodilators.
Cat. No.: HY-117896
CAS No.: 138828-39-4
Target:
Research Areas:
SC-50605 and SC-51146 are second-generation leukotriene B4 (LTB4) receptor antagonists that effectively inhibit LTB4-induced chemotaxis in guinea pigs. SC-50605 targets the LTB4 receptor and has the potential to inhibit inflammatory diseases such as asthma, rheumatoid arthritis, and skin diseases. .
Cat. No.: HY-115500
CAS No.: 1206514-50-2
Research Areas:
PL265 is an orally active dual enkephalinase inhibitor. PL265 is a prodrug of PL254, which can simultaneously and efficiently inhibit neutral endopeptidase (Neprilysin) and Aminopeptidase N. PL265 can effectively protect and significantly increase the local concentration of enkephalins (such as Met-Enkephalin and Leu-Enkephalin) released by cells at the pain or inflammation sites, thereby activating μ and δ opioid receptors to produce a potent analgesic effect. PL254 can also inhibit leukotriene A4 hydrolase (LTA4H), which may contribute to its additional anti-inflammatory effect by reducing the production of pro-inflammatory mediator leukotriene B4 (LTB4). PL265 can be used in non-addictive chronic pain research .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
